Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Large Increase in Short Interest

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 86,000 shares, an increase of 367.4% from the April 15th total of 18,400 shares. Based on an average daily volume of 819,700 shares, the short-interest ratio is currently 0.1 days.

Kazia Therapeutics Trading Up 0.8 %

NASDAQ KZIA opened at $0.29 on Friday. The stock has a fifty day simple moving average of $0.30 and a 200-day simple moving average of $0.39. Kazia Therapeutics has a twelve month low of $0.19 and a twelve month high of $1.39.

Institutional Investors Weigh In On Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. Armistice Capital LLC bought a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,475,555 shares of the company’s stock, valued at approximately $1,088,000. Armistice Capital LLC owned approximately 15.15% of Kazia Therapeutics at the end of the most recent quarter. 30.89% of the stock is owned by hedge funds and other institutional investors.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.